Table 1.
Human breast cancer cell lines and their characteristics
| Immunocytochemistry | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cell lines | BRCA1 status | ER | PR | HER2 | ck5/6 | CK14 | EGFR | cKIT | ||
| MCF10A | Non tumoral | Benign | wild-type | – | – | – | + (90 %) | + (80 %) | + (100 %) | – |
| MCF7 | Tumoral | Luminal | wild-type | 90 % (1+) | 40 % (1/2+) | – | – | – | – | – |
| T47D | Tumoral | Luminal | wild-type | 50 % (1/2+) | 80 % (1/2/+) | – | – | – | +(40 %) | – |
| MDA-MB-231 | Tumoral | TN | wild-type | – | – | – | – | – | + (100 %) | – |
| HCC1937 | Tumoral | TN | 5382insC | – | – | – | + (25 %) | + (20 %) | + (100 %) | – |
| MDA-MB-436 | Tumoral | TN | 5396 + 1G > A | – | – | – | – | – | + (90 %) | – |
| SUM149PT | Tumoral | TN | 2288delT | – | – | – | + (25 %) | + (<1 %) | + (100 %) | – |
| SUM1315MO2 | Tumoral | TN | 185delAG | – | – | – | – | – | + (90 %) | – |
| SUM1315-LXSN | Tumoral | TN | 185delAG | – | – | – | – | – | + (60 %) | – |
| SUM1315-BRCA1 | Tumoral | TN | 185delAG + WT | – | – | – | – | – | + (80 %) | – |
TN: Triple-Negative. The BRCA1mutational status as also the Estrogen Receptor (ER), Progesterone Receptor (PR), HER2 protein, Cytokeratin5/6 (ck5/6), Cytokeratin14 (ck14), Epidermal Growth Factor Receptor (EGFR) and cKIT protein expression status are indicated